Kintara Therapeutics Inc (Nasdaq: KTRA), a United States-based biopharmaceutical company, announced on Wednesday that it has named Mario Lacouture as MD to the REM-001 Scientific Advisory Board.
Dr Lacouture will initially concentrate on Cutaneous Metastatic Breast Cancer (CMBC).
Dr Lacouture is serving as the director of the Oncodermatology Program at the Memorial Sloan Kettering Cancer Center. He is also a professor of dermatology at Weill Cornell Medicine in New York City. He has a medical degree from Javeriana University in Bogota, Colombia and completed an internship in General Surgery at The Cleveland Clinic, residency in dermatology at The University of Chicago, and postdoctoral work at Brigham and Women's Hospital in Boston.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories